Ann Arbor Hospital Murders

FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES $5 MILLION GIFT TO ADVANCE CLINICAL TRIALS IN RARE NEURODEVELOPMENTAL DISORDERS

Retrieved on: 
Friday, December 2, 2022

MIAMI, Dec. 2, 2022 /PRNewswire/ -- The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a $5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmental disorders, a first-of-its-kind flagship center to be directed by Dr. Elizabeth Berry-Kravis. Named the Rush F.A.S.T. Center for Translational Research, it will be the global headquarters for training individuals in how to run neurogenetic clinical trials and deliver innovative interventional therapies that require novel delivery methods and specialized care.

Key Points: 
  • The Center at Rush University Will Be Directed By Dr. Elizabeth Berry-Kravis
    MIAMI, Dec. 2, 2022 /PRNewswire/ --The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a $5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmental disorders, a first-of-its-kind flagship center to be directed by Dr. Elizabeth Berry-Kravis.
  • Center for Translational Research, it will be the global headquarters for training individuals in how to run neurogenetic clinical trials and deliver innovative interventional therapies that require novel delivery methods and specialized care.
  • Today there are over 25 therapeutic programs in the development pipeline for Angelman syndrome, with a majority robustly funded by FAST," said Dr. Allyson Berent, chief science officer at FAST.
  • When a FAST fellow completes their training, they will be able to bring this expertise to other institutions around the world.

FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES $5 MILLION GIFT TO ADVANCE CLINICAL TRIALS IN RARE NEURODEVELOPMENTAL DISORDERS

Retrieved on: 
Friday, December 2, 2022

MIAMI, Dec. 2, 2022 /PRNewswire/ -- The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a $5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmental disorders, a first-of-its-kind flagship center to be directed by Dr. Elizabeth Berry-Kravis. Named the Rush F.A.S.T. Center for Translational Research, it will be the global headquarters for training individuals in how to run neurogenetic clinical trials and deliver innovative interventional therapies that require novel delivery methods and specialized care.

Key Points: 
  • The Center at Rush University Will Be Directed By Dr. Elizabeth Berry-Kravis
    MIAMI, Dec. 2, 2022 /PRNewswire/ --The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a $5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmental disorders, a first-of-its-kind flagship center to be directed by Dr. Elizabeth Berry-Kravis.
  • Center for Translational Research, it will be the global headquarters for training individuals in how to run neurogenetic clinical trials and deliver innovative interventional therapies that require novel delivery methods and specialized care.
  • Today there are over 25 therapeutic programs in the development pipeline for Angelman syndrome, with a majority robustly funded by FAST," said Dr. Allyson Berent, chief science officer at FAST.
  • When a FAST fellow completes their training, they will be able to bring this expertise to other institutions around the world.